SEC Form 4 · accession 0001104659-16-145549
Aralez Pharmaceuticals Inc. · ARLZ
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Robert Paul Harris
Director
Period of report
Sep 15, 2016
Accepted (ET)
Sep 19, 2016 · 7:57 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001660719
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Shares, without par valueF1 | Sep 15, 2016 | S | 75,000 | $5.60 | D | 669,094 | D | |
| Common Shares, without par valueF1,F2 | Sep 15, 2016 | S | 75,000 | $6.0429 | D | 594,094 | D | |
| Common Shares, without par value | holding | — | — | — | 600,188 | I | By spouse |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 16, 2016.
- F2This transaction was executed in multiple trades at prices ranging from $6.00 to $6.13. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.